Featured Content

Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity

This PD-1 inhibitor is effective for treating melanoma, though it can be highly toxic and there is a lack of biomarkers for predicting a response.

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

Avelumab: A Landmark Approval in Metastatic Merkel Cell Carcinoma

This approval is likely to dramatically improve the otherwise dismal outcomes for patients in this clinical setting.

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer ...

Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history ...

More Features>>>

Skin Cancer Resources

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters